Ranger Investment Management L.P. Has $60.65 Million Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Ranger Investment Management L.P. reduced its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 4.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 658,229 shares of the medical instruments supplier's stock after selling 27,226 shares during the period. LeMaitre Vascular makes up approximately 3.8% of Ranger Investment Management L.P.'s investment portfolio, making the stock its 2nd biggest position. Ranger Investment Management L.P. owned 2.93% of LeMaitre Vascular worth $60,649,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. The Manufacturers Life Insurance Company grew its holdings in LeMaitre Vascular by 7.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 11,273 shares of the medical instruments supplier's stock worth $1,047,000 after acquiring an additional 804 shares during the last quarter. FMR LLC boosted its position in LeMaitre Vascular by 330.6% during the third quarter. FMR LLC now owns 10,568 shares of the medical instruments supplier's stock valued at $982,000 after acquiring an additional 8,114 shares during the last quarter. Verition Fund Management LLC bought a new stake in LeMaitre Vascular during the third quarter valued at $415,000. Quadrature Capital Ltd acquired a new stake in LeMaitre Vascular during the 3rd quarter worth about $281,000. Finally, Stifel Financial Corp lifted its stake in shares of LeMaitre Vascular by 10.8% in the 3rd quarter. Stifel Financial Corp now owns 72,194 shares of the medical instruments supplier's stock valued at $6,706,000 after purchasing an additional 7,060 shares during the period. 84.64% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price target for the company. Finally, Lake Street Capital upped their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, LeMaitre Vascular has an average rating of "Moderate Buy" and a consensus target price of $95.25.

LeMaitre Vascular Stock Down 0.9 %

LeMaitre Vascular stock traded down $0.77 during midday trading on Monday, reaching $82.05. The stock had a trading volume of 39,227 shares, compared to its average volume of 158,960. The firm has a market capitalization of $1.85 billion, a PE ratio of 44.84, a P/E/G ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12 month low of $62.39 and a 12 month high of $109.58. The firm's 50-day moving average price is $89.17 and its 200 day moving average price is $93.74.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts' consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $55.81 million for the quarter, compared to analysts' expectations of $55.99 million. Equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were issued a dividend of $0.20 per share. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a yield of 0.98%. LeMaitre Vascular's dividend payout ratio is 41.24%.

Insiders Place Their Bets

In related news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now owns 5,564 shares of the company's stock, valued at approximately $456,915.68. This represents a 26.53 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.